Table 4 ENO2 haplotypes showing nominal significant association to schizophrenia
Model effect1 | Individual effect | |||||
|---|---|---|---|---|---|---|
Overall Country | Case | Control | ||||
Markers | P | P | n (freq) | n (freq) | OR (CI: 95%) | P2 |
rs2238116, rs3213434 | 0.01 | 0.59 | ||||
AC* | 1030 (0.72) | 1730 (0.71) | 1.00 (1.00-1.00) | 0.51 | ||
AT | 20 (0.01) | 69 (0.03) | 0.48 (0.29–0.80) | 0.0007 | ||
GT | 388 (0.27) | 655 (0.27) | 1.00 (0.86–1.17) | 0.74 | ||
rs1057077, rs3213434 | 0.0026 | 0.32 | ||||
TC* | 1087 (0.72) | 1782 (0.70) | 1.00 (1.00-1.00) | 0.33 | ||
TT | 18 (0.01) | 69 (0.03) | 0.42 (0.35–0.51) | 0.0006 | ||
AT | 403 (0.27) | 679 (0.27) | 0.99 (0.58–1.69) | 0.92 | ||
rs710415, rs3213434 | 0.01 | 0.37 | ||||
AC* | 1091 (0.72) | 1772 (0.71) | 1.00 (1.00-1.00) | 0.31 | ||
AT | 18 (0.01) | 63 (0.03) | 0.46 (0.27–0.79) | 0.0009 | ||
GT | 399 (0.26) | 675 (0.27) | 0.97 (0.84–1.13) | 0.92 | ||
rs2238116, rs1057077, rs3213434 | 0.0045 | 0.59 | ||||
ATC* | 1021 (0.72) | 1725 (0.71) | 1.00 (1.00-1.00) | 0.57 | ||
ATT | 17 (0.01) | 66 (0.03) | 0.43 (0.36–0.52) | 0.001 | ||
GAT | 388 (0.27) | 653 (0.27) | 1.01 (0.83–1.23) | 0.71 | ||
rs2238116, rs710415, rs3213434 | 0.01 | 0.61 | ||||
AAC* | 1025 (0.72) | 1712 (0.71) | 1.00 (1.00-1.00) | 0.63 | ||
AAT | 17 (0.01) | 61 (0.03) | 0.47 (0.27–0.81) | 0.001 | ||
GGT | 386 (0.27) | 643 (0.27) | 1.01 (0.87–1.18) | 0.67 | ||
rs1057077, rs710415, rs3213434 | 0.01 | 0.32 | ||||
TAC* | 1085 (0.72) | 1765 (0.71) | 1.00 (1.00-1.00) | 0.50 | ||
TAT | 18 (0.01) | 63 (0.03) | 0.47 (0.47–0.47) | 0.004 | ||
AGT | 399 (0.27) | 668 (0.27) | 0.99 (0.99-0.99) | 0.95 | ||
rs2238116, rs1057077, rs710415, | 0.01 | 0.60 | ||||
rs3213434 | ||||||
ATAC* | 1019 (0.72) | 1710 (0.71) | 1.00 (1.00-1.00) | 0.68 | ||
ATAT | 17 (0.01) | 61 (0.03) | 0.47 (0.39–0.57) | 0.004 | ||
GAGT | 386 (0.27) | 643 (0.27) | 1.02 (0.84–1.24) | 0.70 | ||